|
Expert Panel Discussion: GFH009 CDK9 inhibitor in Acute Myeloid Leukemia
Tuesday, May 30, 2023 | 8:00 AM ET
Hosted by SELLAS Life Sciences Group (NASDAQ: SLS)
| |
Join us for a virtual panel discussion with SELLAS Life Sciences, featuring hematology-oncology specialists Tapan Kadia, MD (The University of Texas MD Anderson Cancer Center), Joshua Zeidner, MD (University of North Carolina Lineberger Comprehensive Cancer Center), and Omer Jamy, MD (O’Neal Comprehensive Cancer Center at the University of Alabama) who will discuss the treatment landscape for acute myeloid leukemia (AML) and the potential for GFH009 to address unmet medical needs for patients with relapsed and/or refractory AML.
GFH009 is a clinical stage small molecule, highly selective CDK9 inhibitor that SELLAS is investigating for treatment of patients with hematologic malignancies and solid tumors. SELLAS plans to commence a Phase 2a clinical trial during the second quarter of 2023 with GFH009 in combination with venetoclax and azacitidine in AML patients.
A live question and answer session will follow the formal discussion.
| | |
|
Registration information
You are required to register in advance for the webcast. For those who are unable to listen at this time, a replay of the call will be available by clicking here.
| |  |
|
Q&A information
If you would like to ask a question during the live Q&A, please submit your request to questions@lifesciadvisors.com.
| |
|
Tapan Kadia, MD, is a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He serves as co-Leader of the sections of AML and developmental therapeutics and is the associate program director of the Leukemia Fellowship program. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and acute lymphocytic leukemia (ALL). He is primary investigator on numerous trials in AML, T-cell leukemias, bone marrow failure states, and is a leader in these. He has received numerous academic and clinical honors and awards for his studies and clinical research. Additionally, he’s authored over 375 peer-reviewed articles, numerous abstracts, and has been invited nationally and internationally for presentation of his research.
| |
|
Joshua Zeidner, MD, is Associate Professor of Medicine, Chief of Leukemia Research and Associate Chief of Research, Division of Hematology at University of North Carolina Lineberger Comprehensive Cancer Center. Dr. Zeidner's research involves the discovery of innovative methods to improve outcomes, drug discovery and development, and clinical trial design in AML, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). He leads the Leukemia Clinical Trials Research Protocol Office Disease (POD) Group which oversees clinical trials for acute leukemia, MDS, and MPN. He serves as the Principal Investigator of various industry-sponsored, investigator-initiated, and academic collaborative clinical trials evaluating novel agents in MDS and AML.
| |
|
Omer Jamy, MD, is an Assistant Professor of Medicine at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB). He currently serves as the Associate Director of the Bone Marrow Transplant (BMT) Program at UAB and is the BMT course director for international visiting medical students. He co-leads the adolescents and young adult (AYA) acute leukemia working group at UAB. Dr. Jamy’s primary research interest lies in being able to offer novel therapeutic options to his patients with high-risk myeloid malignancies, including those needing allogeneic stem cell transplantation. He serves as the principal investigator on numerous clinical trials focusing on (AML, chronic myelogenous leukemia (CML), and allogeneic stem cell transplantation. He has authored over 40 peer-reviewed articles, including several investigator-initiated trials.
| |
|
Copyright © 2023 LifeSci Advisors, LLC, All rights reserved.
This message contains confidential and proprietary information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this email from your system. All market prices, data and other information contained in this email are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect the views of LifeSci Advisors, LLC, its affiliates, subsidiaries or agents. The message is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Before opening any attachments please check them for viruses and defects.
| | | | |
